274 related articles for article (PubMed ID: 9550378)
1. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
[TBL] [Abstract][Full Text] [Related]
2. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
[TBL] [Abstract][Full Text] [Related]
4. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
5. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
Blazar BR; Taylor PA; Vallera DA
J Immunol; 1994 Apr; 152(7):3665-74. PubMed ID: 8144942
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
8. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
Hirsch R; Archibald J; Gress RE
J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
[TBL] [Abstract][Full Text] [Related]
9. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
[TBL] [Abstract][Full Text] [Related]
10. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
Chapoval AI; Nelson H; Thibault C
J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
[TBL] [Abstract][Full Text] [Related]
12. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
13. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
14. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
[TBL] [Abstract][Full Text] [Related]
16. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
Friedman TM; Gilbert M; Briggs C; Korngold R
J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.
Zeng M; Guinet E; Nouri-Shirazi M
Transpl Immunol; 2009 Dec; 22(1-2):82-92. PubMed ID: 19635560
[TBL] [Abstract][Full Text] [Related]
18. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
19. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
Jones SC; Friedman TM; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
[TBL] [Abstract][Full Text] [Related]
20. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells.
Carteron NL; Wofsy D; Seaman WE
J Immunol; 1988 Feb; 140(3):713-6. PubMed ID: 2448372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
